Aprea Therapeutics, Inc. (APRE)
NASDAQ·Healthcare·Biotechnology
$0.85
-1.87%
Mkt Cap $5.40M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 16, 2026 | $3.34K | $3.34K | +0.00% | -$0.38 | -$0.32 | +15.79% | — | — |
| Q4 2025 Nov 12, 2025 | — | $1.85K | — | -$0.11 | -$0.47 | -327.27% | — | — |
| Q3 2025 Aug 12, 2025 | — | $118.11K | — | -$0.77 | -$0.53 | +31.17% | — | — |
| Q2 2025 May 14, 2025 | — | $162.46K | — | -$0.65 | -$0.66 | -0.87% | — | — |
| Q1 2025 Mar 25, 2025 | $225.00K | $205.82K | -8.53% | -$0.69 | -$0.49 | +28.99% | — | — |
| Q4 2024 Nov 7, 2024 | $225.00K | $354.62K | +57.61% | -$0.75 | -$0.64 | +14.67% | — | — |
| Q3 2024 Aug 12, 2024 | $50.00K | $561.57K | +1023.15% | -$0.64 | -$0.58 | +9.38% | — | — |
| Q2 2024 May 14, 2024 | — | $380.57K | — | -$0.78 | -$0.67 | +14.10% | — | — |
| Q1 2024 Mar 26, 2024 | $110.00K | $14.07K | -87.20% | -$0.56 | -$0.92 | -64.29% | — | — |
| Q4 2023 Nov 9, 2023 | $110.00K | $319.47K | +190.43% | -$1.08 | -$0.86 | +20.37% | — | — |
| Q3 2023 Aug 10, 2023 | — | $249.69K | — | -$1.43 | -$0.87 | +39.16% | — | — |
| Q2 2023 May 15, 2023 | — | — | — | -$1.51 | -$1.34 | +11.26% | — | — |
| Q1 2023 Mar 30, 2023 | — | — | — | -$2.60 | -$0.92 | +64.62% | — | — |
| Q4 2022 Nov 9, 2022 | — | — | — | -$5.60 | -$2.40 | +57.14% | — | — |
| Q3 2022 Aug 11, 2022 | — | — | — | -$7.60 | -$19.80 | -160.53% | — | — |
| Q2 2022 May 16, 2022 | — | — | — | -$7.60 | -$7.20 | +5.26% | — | — |
| Q1 2022 Mar 15, 2022 | — | — | — | -$8.80 | -$7.20 | +18.18% | — | — |
| Q4 2021 Nov 8, 2021 | — | — | — | -$8.80 | -$9.00 | -2.27% | — | — |
| Q3 2021 Aug 12, 2021 | — | — | — | -$9.40 | -$9.60 | -2.13% | — | — |
| Q2 2021 May 6, 2021 | — | — | — | -$10.40 | -$9.20 | +11.54% | — | — |